Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Filings indexed 829 across all filing types
Latest filing 2024-02-03 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2024-02-03 English
FORM 4
Director's Dealing
2024-02-03 English
FORM 4
Director's Dealing
2024-02-03 English
FORM 4
Director's Dealing
2024-02-03 English
FORM 8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. It amends a previously filed Form 8-K to include financial statements and pro forma financial information related to an acquisition. The document includes references to audited and unaudited financial statements of the acquired company and pro forma combined financials. However, the document itself is a regulatory filing updating a prior report rather than a full annual or interim report. It is not an earnings release, proxy, or other specific category. Given it is an amended current report with financial statements and pro forma info, it fits best under Regulatory Filings (RNS) as it does not constitute a full Annual Report (10-K) or Interim Report (IR) by itself, but rather an SEC current report amendment with financial disclosures.
2024-02-02 English
FORM 3
Director's Dealing
2024-02-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.